Vanguard Global Advisers
HAE icon

Vanguard Global Advisers’s Haemonetics HAE Stock Holding History

Vanguard Global Advisers’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
21,703
+3,062
+16% +$197K ﹤0.01% 1412
2026
Q1 		$1.05M Buy
+18,641
New +$1.21M ﹤0.01% 1628

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's HAE Position: Q2 2026 in Review

Vanguard Global Advisers increased its Haemonetics (HAE) stake by 16% in Q2 2026, buying an estimated $197K and bringing the position to 21,703 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Vanguard Global Advisers first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 326 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Vanguard Global Advisers held 21,703 shares of Haemonetics worth $1.63M as of Q2 2026.
  • Vanguard Global Advisers bought 3,062 Haemonetics shares in Q2 2026, an estimated $197K.
  • Haemonetics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1412 holding.
  • Vanguard Global Advisers first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
  • 326 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.